SMT201600090B - Composizioni monovalenti per il legame a cd28 e metodi di utilizzo - Google Patents

Composizioni monovalenti per il legame a cd28 e metodi di utilizzo

Info

Publication number
SMT201600090B
SMT201600090B SM201600090T SM201600090T SMT201600090B SM T201600090 B SMT201600090 B SM T201600090B SM 201600090 T SM201600090 T SM 201600090T SM 201600090 T SM201600090 T SM 201600090T SM T201600090 B SMT201600090 B SM T201600090B
Authority
SM
San Marino
Prior art keywords
monoval
bond
compositions
methods
monoval compositions
Prior art date
Application number
SM201600090T
Other languages
English (en)
Italian (it)
Inventor
Murray Mckinnon
Steven G Nadler
Suzanne J Suchard
Brendan Classon
Steve Holmes
Olga Ignatovich
Christopher Plummer
Steve Grant
Original Assignee
Bristol Myers Squibb Co
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41226147&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600090(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co, Domantis Ltd filed Critical Bristol Myers Squibb Co
Publication of SMT201600090B publication Critical patent/SMT201600090B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
SM201600090T 2008-07-18 2016-03-29 Composizioni monovalenti per il legame a cd28 e metodi di utilizzo SMT201600090B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8207808P 2008-07-18 2008-07-18
US16212109P 2009-03-20 2009-03-20
PCT/US2009/050985 WO2010009391A1 (en) 2008-07-18 2009-07-17 Compositions monovalent for cd28 binding and methods of use

Publications (1)

Publication Number Publication Date
SMT201600090B true SMT201600090B (it) 2016-04-29

Family

ID=41226147

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600090T SMT201600090B (it) 2008-07-18 2016-03-29 Composizioni monovalenti per il legame a cd28 e metodi di utilizzo

Country Status (30)

Country Link
US (6) US8168759B2 (ko)
EP (2) EP2321352B1 (ko)
JP (3) JP5675608B2 (ko)
KR (2) KR101791372B1 (ko)
CN (2) CN105936648B (ko)
AR (1) AR072571A1 (ko)
AU (1) AU2009270726B2 (ko)
CA (1) CA2731220C (ko)
CL (2) CL2011000117A1 (ko)
CO (1) CO6341641A2 (ko)
CY (1) CY1121796T1 (ko)
DK (2) DK2321352T3 (ko)
EA (1) EA024585B1 (ko)
ES (2) ES2730727T3 (ko)
HK (1) HK1155178A1 (ko)
HR (2) HRP20160329T1 (ko)
HU (2) HUE045249T2 (ko)
IL (2) IL210413A (ko)
LT (1) LT2700651T (ko)
ME (1) ME02396B (ko)
MX (1) MX2011000501A (ko)
NZ (1) NZ590343A (ko)
PE (2) PE20110385A1 (ko)
PL (2) PL2321352T3 (ko)
PT (2) PT2321352E (ko)
RS (2) RS58904B1 (ko)
SI (2) SI2700651T1 (ko)
SM (1) SMT201600090B (ko)
TW (2) TW201336510A (ko)
WO (1) WO2010009391A1 (ko)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1888641T3 (da) 2005-05-18 2012-04-23 Ablynx Nv Serumalbuminbindende proteiner
US20110097339A1 (en) * 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
ME02396B (me) * 2008-07-18 2016-08-31 Bristol Myers Squibb Co Smješe monovalentne za vezivanje sa cd28 i metodi upotrebe
US8946128B2 (en) * 2009-02-25 2015-02-03 Nextera As Signal sequence-independent pIX phage display
FR2951176A1 (fr) * 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
EP2361935A1 (en) * 2010-02-18 2011-08-31 TcL Pharma Anti-CD28 humanized antibodies
DK2536764T3 (en) 2010-02-18 2018-09-17 Ose Immunotherapeutics ANTI-CD28 HUMANIZED ANTIBODIES
US9000130B2 (en) * 2010-06-08 2015-04-07 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP5768022B2 (ja) * 2012-03-19 2015-08-26 株式会社東芝 メモリコントローラ、記憶装置、誤り訂正装置および誤り訂正方法
WO2014120916A1 (en) 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Pegylated domain antibodies monovalent for cd28 binding and methods of use
CA2935143C (en) * 2013-12-27 2024-05-07 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
CA2943177A1 (en) * 2014-03-19 2015-09-24 Bristol-Myers Squibb Company Methods of treating transplant rejection using a domain antibody directed against cd40l
CN107108724A (zh) 2014-09-12 2017-08-29 豪夫迈·罗氏有限公司 半胱氨酸改造抗体和缀合物
KR20170062505A (ko) * 2014-09-30 2017-06-07 브리스톨-마이어스 스큅 컴퍼니 Cd28에 대해 지시된 도메인 항체를 사용하여 전신성 홍반성 루푸스를 치료하는 방법
US20190086405A1 (en) 2016-03-16 2019-03-21 Bristol-Myers Squibb Company Methods of diagnosing and treating lupus
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
CN110770255A (zh) 2017-04-11 2020-02-07 印希彼有限公司 具有受限cd3结合的多特异性多肽构建体及其使用方法
EP3806848A2 (en) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
EP3830579A1 (en) 2018-08-03 2021-06-09 Bristol-Myers Squibb Company Methods for detecting anti-drug antibodies
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
AU2020234111A1 (en) * 2019-03-14 2021-10-14 Biond Biologics Ltd. Small shedding blocking agents
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
WO2021111441A1 (en) * 2019-12-02 2021-06-10 Biond Biologics Ltd. Use of mmp inhibition
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
AU2021213177A1 (en) * 2020-01-29 2022-08-18 Inhibrx Biosciences, Inc. CD28 single domain antibodies and multivalent and multispecific constructs thereof
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
US20230303699A1 (en) * 2020-08-04 2023-09-28 Exelixis, Inc. Pd-l1 binding agents and uses thereof
WO2022212784A1 (en) 2021-03-31 2022-10-06 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
CA3230990A1 (en) * 2021-09-06 2023-03-09 Anna FRIDMAN-DROR Cd28 shedding blocking agents
WO2023215799A1 (en) * 2022-05-04 2023-11-09 Janux Therapeutics, Inc. Tumor activated multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
WO2023215498A2 (en) * 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024077118A2 (en) 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839295A (en) 1984-06-08 1989-06-13 Pierce Chemical Company Measurement of protein using bicinchoninic acid
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ES2338791T3 (es) 1992-08-21 2010-05-12 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
CA2214889C (en) 1995-03-10 2005-05-24 Hans Koll Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and a process for the production thereof
PT859841E (pt) 1995-08-18 2002-11-29 Morphosys Ag Bibliotecas de proteinas/ (poli) peptidos
CA2292415A1 (en) 1997-06-20 1998-12-30 Innogenetics N.V. B7-binding molecules for treating immune diseases
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2325983C (en) 1998-04-20 2009-02-17 Genzyme Corporation Drug delivery of proteins from polymeric blends
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
CA2372198A1 (en) 1999-05-14 2000-11-23 Medical Research Council Protein scaffold and its use to multimerise monomeric polypeptides
US20020006403A1 (en) * 1999-12-14 2002-01-17 Xue-Zhong Yu CD28-specific antibody compositions for use in methods of immunosuppression
ES2353273T3 (es) * 2000-12-26 2011-02-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos anti-cd28.
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
CA2763913C (en) 2001-08-10 2014-10-28 Aberdeen University Antigen binding domains
WO2003031611A2 (en) 2001-10-05 2003-04-17 Cangene Corporation Phagemid display system
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
DE10156482A1 (de) * 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US7635472B2 (en) 2003-05-31 2009-12-22 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
UA94213C2 (ru) * 2004-09-17 2011-04-26 Домантис Лимитед Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания
GB0614093D0 (en) 2006-07-14 2006-08-23 Bae Systems Plc Deployable antenna system
WO2008071447A2 (en) * 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
ME02396B (me) * 2008-07-18 2016-08-31 Bristol Myers Squibb Co Smješe monovalentne za vezivanje sa cd28 i metodi upotrebe
RU2011110459A (ru) 2008-08-21 2012-09-27 Октафарма АГ (CH) Рекомбинантно полученный человеческий фактор viii и ix
CA2943177A1 (en) * 2014-03-19 2015-09-24 Bristol-Myers Squibb Company Methods of treating transplant rejection using a domain antibody directed against cd40l
KR20170062505A (ko) * 2014-09-30 2017-06-07 브리스톨-마이어스 스큅 컴퍼니 Cd28에 대해 지시된 도메인 항체를 사용하여 전신성 홍반성 루푸스를 치료하는 방법

Also Published As

Publication number Publication date
PT2700651T (pt) 2019-06-19
US20180142023A1 (en) 2018-05-24
HK1155178A1 (zh) 2012-05-11
JP5876134B2 (ja) 2016-03-02
RS58904B1 (sr) 2019-08-30
CO6341641A2 (es) 2011-11-21
ES2562629T3 (es) 2016-03-07
US20150299321A1 (en) 2015-10-22
MX2011000501A (es) 2011-05-23
JP2015120695A (ja) 2015-07-02
PL2700651T3 (pl) 2019-09-30
CA2731220C (en) 2017-10-10
PE20140852A1 (es) 2014-07-14
US20100028354A1 (en) 2010-02-04
US12012452B2 (en) 2024-06-18
CY1121796T1 (el) 2020-07-31
CN105936648A (zh) 2016-09-14
LT2700651T (lt) 2019-06-25
KR101660057B1 (ko) 2016-09-26
ES2730727T3 (es) 2019-11-12
TW201336510A (zh) 2013-09-16
IL210413A0 (en) 2011-03-31
CN102159590A (zh) 2011-08-17
SI2321352T1 (sl) 2016-04-29
JP2016063830A (ja) 2016-04-28
IL251320A0 (en) 2017-05-29
JP5675608B2 (ja) 2015-02-25
CA2731220A1 (en) 2010-01-21
KR20110041527A (ko) 2011-04-21
EP2700651B1 (en) 2019-04-10
EP2321352A1 (en) 2011-05-18
SI2700651T1 (sl) 2019-08-30
CN105936648B (zh) 2020-06-16
EA201100239A1 (ru) 2011-10-31
PE20110385A1 (es) 2011-06-22
PL2321352T3 (pl) 2016-06-30
CL2012002428A1 (es) 2013-01-11
CL2011000117A1 (es) 2011-06-17
US8168759B2 (en) 2012-05-01
JP6058833B2 (ja) 2017-01-11
IL210413A (en) 2017-04-30
EP2321352B1 (en) 2016-01-06
HUE045249T2 (hu) 2019-12-30
AR072571A1 (es) 2010-09-08
WO2010009391A1 (en) 2010-01-21
DK2700651T3 (da) 2019-07-22
HRP20160329T1 (hr) 2016-04-22
US20210047414A1 (en) 2021-02-18
PT2321352E (pt) 2016-03-18
US10919965B2 (en) 2021-02-16
TWI450725B (zh) 2014-09-01
AU2009270726A1 (en) 2010-01-21
US20130109846A1 (en) 2013-05-02
EA024585B1 (ru) 2016-10-31
KR101791372B1 (ko) 2017-10-27
US9085629B2 (en) 2015-07-21
IL251320B (en) 2019-01-31
KR20160113322A (ko) 2016-09-28
US20120201814A1 (en) 2012-08-09
US9908937B2 (en) 2018-03-06
AU2009270726B2 (en) 2015-07-09
HUE029982T2 (en) 2017-04-28
RS54675B1 (en) 2016-08-31
TW201006494A (en) 2010-02-16
DK2321352T3 (en) 2016-04-04
EP2700651A1 (en) 2014-02-26
NZ590343A (en) 2012-10-26
HRP20190966T1 (hr) 2019-07-26
JP2011528551A (ja) 2011-11-24
US8454959B2 (en) 2013-06-04
ME02396B (me) 2016-08-31

Similar Documents

Publication Publication Date Title
SMT201600090B (it) Composizioni monovalenti per il legame a cd28 e metodi di utilizzo
SMT201500282B (it) Strumento per lavorare il terreno
HK1206421A1 (en) Anti-cxcr1 compositions and methods cxcr1
IL211147A0 (en) 1h-benzimidazole-5-carboxamides as anti-inflammatory agents
DK2634232T3 (da) Sammensætninger
BRPI1013748A2 (pt) "compostos de vinil-indazolila"
BRPI0810634A2 (pt) Composições fungicidas
BRPI0924929A2 (pt) "unidade de transdutor"
PT2424374T (pt) Composições de limpeza e métodos para utilização das mesmas
BRPI0922181A2 (pt) partículas de anti-corrosivo
BRPI0907078A2 (pt) "artigo laminado"
BRPI0914533A2 (pt) "métodos"
FR2955590B1 (fr) Compositions de nettoyage a base d'hydrochlorofluoroolefine
ZA201103338B (en) Cleansing compositions
BR112012003701A2 (pt) "novos antagonistas de quinolina-hepcidina"
BRPI1012055A2 (pt) "piperidinas substituídas"
EP2179815A4 (en) BINDING COMPOSITION
FR2965705B1 (fr) Compositions d'edulcorants
DK2170292T3 (da) Atazanavirholdige sammensætninger i tabletform
IT1395687B1 (it) Dispositivo per l'applicazione di etichette termoretraibili
DK2468819T3 (da) Kobberholdige polyester-polyamidsammensætninger
MA30860B1 (fr) Myrtillier denomme "c97-390"
ITUD20080029A1 (it) Apparecchiatura per operazioni didattiche di odontoiatria
DE112008000091A5 (de) Massebondverbindung
GB0713553D0 (en) Bonding compositions